Ciphergen Biosystems Discovers Protein Biomarkers Useful for Diagnosis of Early-Stage Ovarian Cancer
April 16 2007 - 10:00AM
PR Newswire (US)
Data Presented at American Association for Cancer Research Annual
Meeting FREMONT, Calif., April 16 /PRNewswire-FirstCall/ --
Ciphergen Biosystems, Inc. (NASDAQ:CIPH) today presented data on
the discovery of several protein biomarkers that may be potential
diagnostic markers in detection of early- stage ovarian cancer.
These findings support one of three diagnostic programs that
Ciphergen currently has under development for ovarian cancer. These
findings were presented at the American Association for Cancer
Research Annual Meeting in Los Angeles, Calif. "Development of a
reliable test for the diagnosis of early-stage ovarian cancer
should contribute to improving overall survival in patients," said
Robert C. Bast, Jr., M.D., Vice President of Translational
Medicine, and Professor of Experimental Therapeutics at, M.D.
Anderson Cancer Center, University of Texas, co-author of the
presentation and member of the Ciphergen Scientific Advisory Board.
Ciphergen and its collaborators discovered four proteins in urine
that separate women with early cancer from healthy individuals with
a sensitivity of 56% and a specificity of 95%. These results
suggest the possibility that these proteins in combination with
other biomarkers, could aid in the diagnosis of early-stage ovarian
cancer. To elucidate these findings Ciphergen employed protein
expression profiling methods to analyze urine samples from 400
women, including 288 women with epithelial ovarian cancer, 52 with
early stage disease and 176 with late stage disease, 74 women with
benign ovarian disease and 98 normal, healthy controls. "These
promising results provide the foundation for additional studies
across a larger population of women," said Eric T. Fung, M.D.,
Ph.D., Chief Scientific Officer for Ciphergen Biosystems. "By
demonstrating that these findings are reproducible, Ciphergen hopes
to advance these markers beyond the clinical validation process and
into clinical trials." About Ciphergen's Ovarian Cancer Diagnostic
Program Ciphergen has multiple ovarian cancer diagnostic tests in
development, including an ovarian cancer triage test designed to
distinguish between benign and malignant pelvic masses, one to
predict recurrence of ovarian cancer and a test to aid physicians
in identifying women considered at high risk for ovarian cancer.
These findings support Ciphergen's diagnostic program with
high-risk, early-stage disease. Ciphergen is currently enrolling
patients in a prospective clinical trial for its ovarian cancer
triage test to evaluate whether the positive predictive value of
the test is better than the current standard of care -- physical
and radiological exam -- for distinguishing benign from malignant
ovarian tumors. Enrollment information is available at
clinicaltrials.gov, identifier NCT00436189. Ciphergen's
comprehensive diagnostic development program is being conducted
with several leading collaborators at The Johns Hopkins School of
Medicine, The University of Texas M.D. Anderson Cancer Center,
University College London, and the University of Kentucky. About
Ovarian Cancer Commonly known as the "silent killer," ovarian
cancer leads to approximately 15,000 deaths each year in the United
States, according to the American Cancer Society. Approximately
20,000 new cases are diagnosed each year, with the majority in
patients diagnosed with late stage disease where the cancer has
spread beyond the ovary. The prognosis is poor in these patients,
leading to the high mortality from this disease. A diagnostic test
is needed that can provide adequate predictive value to stratify
patients with a pelvic mass into high risk of invasive ovarian
cancer versus those with low risk, as well as a screening test for
the diagnosis of early-stage ovarian cancer, which is essential for
improving overall survival in patients. Ovarian cancer has up to a
90% cure rate following surgery and/or chemotherapy if detected in
stage 1. About Ciphergen Ciphergen Biosystems, Inc. is dedicated to
the discovery, development and commercialization of novel
high-value diagnostic tests that help physicians diagnose, treat
and improve outcomes for patients. Ciphergen, along with its
prestigious scientific collaborators, has ongoing diagnostic
programs in oncology, cardiology and women's health with an initial
focus in ovarian cancer. Based in Fremont, California, more
information about Ciphergen can be found on the Web at
http://www.ciphergen.com/. Safe Harbor Statement This news release
contains forward-looking statements that involve significant risks
and uncertainties, including those discussed below and others that
can be found in Ciphergen's Form 10-K for the year ended Dec. 31,
2006, and in Ciphergen's periodic reports on Form 10-Q and Form
8-K. Ciphergen is providing this information as of the date of this
news release and does not undertake any obligation to update any
forward-looking statements contained in this document as a result
of new information, future events or otherwise. The scientific
information discussed in this news release is preliminary and
investigative. No forward-looking statement can be guaranteed and
actual results may differ materially from those Ciphergen projects.
Discovery or identification of new protein biomarkers cannot be
guaranteed and movement beyond the clinical validation process to a
test that successfully screens patients for ovarian cancer is
uncertain; consequently, there can be no guarantee that the
identification of potential diagnostic markers will be successful
or be an appropriate basis for a commercially available diagnostic
kit for screening ovarian cancer. DATASOURCE: Ciphergen Biosystems,
Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen
Biosystems, Inc., +1-510-505-2233; or media, Lori Murray of
WeissComm Partners, +1-415-946-1070 Web site:
http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024